Prepared by:
RTI International
Evidence-Based Practice Center,
Research Triangle Park, North Carolina
Russell P. Harris, M.D., M.P.H.
Linda J. Lux, M.P.A.
Audrina J. Bunton, B.A.
Sonya F. Sutton, B.S.P.H.
Kathleen N. Lohr, Ph.D.
Katrina P. Donahue, M.D.
B. Lynn Whitener, Dr.P.H., M.S.L.S.
Saif S. Rathore, B.A.
File Name Description Software Version File Size _____________________________________________________________________________________________________ 01front.doc Microsoft Word® Document MS Word® 2002 40KB 5 pages Contents: Cover, Title Page, Preface _____________________________________________________________________________________________________ 02abstr.doc Microsoft Word® Document MS Word® 2002 29KB 3 pages Contents: Structured Abstract: Context, Objective, Data Sources, Study Selection, Data Extraction, Data Synthesis, Conclusion _____________________________________________________________________________________________________ 03conts.doc Microsoft Word® Document MS Word® 2002 570KB 2 pages Contents: Table of Contents _____________________________________________________________________________________________________ 04chap1.doc Microsoft Word® Document MS Word® 2002 42KB 3 pages Contents: Chapter 1. Introduction _____________________________________________________________________________________________________ 05chap2.doc Microsoft Word® Document MS Word® 2002 30KB 3 pages Contents: Chapter 2. Methods: Analytic Framework and Key Questions, Search Strategy, Production of the Systematic Evidence Review _____________________________________________________________________________________________________ 06chap3.doc Microsoft Word® Document MS Word® 2002 865KB 24 pages Contents: Chapter 3. Results: Presence of a Detectable Preclinical Period; Accuracy and Acceptability of Screening Tests; Efficacy and Effectiveness of Treatment; Severe Visual Impairment; Chronic Renal Failure; Lower Extremity Amputations; Cardiovascular Events; Early Treatment of Impaired Fasting Glucose/Impaired Glucose Tolerance; Harms of Screening and Treatment; Costs and Cost-Effectiveness of Screening and Earlier Treatment _____________________________________________________________________________________________________ 07chap4.doc Microsoft Word® Document MS Word® 2002 30KB 3 pages Contents: Chapter 4. Discussion: Effects of Screening, Recommendations for Further Research _____________________________________________________________________________________________________ 08refs.doc Microsoft Word® Document MS Word® 2002 100KB 13 pages Contents: References _____________________________________________________________________________________________________ 09appa.doc Microsoft Word® Document MS Word® 2002 27KB 2 pages Contents: Appendix A. Acknowledgements _____________________________________________________________________________________________________ 10etbl1.doc Microsoft Word® Document MS Word® 2002 79KB 4 pages Contents: Appendix B: Evidence Table 1. Properties and Yield of Screening Tests _____________________________________________________________________________________________________ 11etbl2.doc Microsoft Word® Document MS Word® 2002 52KB 2 pages Contents: Appendix B: Evidence Table 2. Studies of Laser Photocoagulation _____________________________________________________________________________________________________ 12etbl3.doc Microsoft Word® Document MS Word® 2002 89KB 1 page Contents: Appendix B: Evidence Table 3. Studies of Tight Glycemic Control _____________________________________________________________________________________________________ 13etbl4.doc Microsoft Word® Document MS Word® 2002 152KB 5 pages Contents: Appendix B: Evidence Table 4. Studies of Antihypertensive, ACE Inhibitors and ARB Medications _____________________________________________________________________________________________________ 14etbl5.doc Microsoft Word® Document MS Word® 2002 61KB 4 pages Contents: Appendix B: Evidence Table 5. Studies of Foot Care _____________________________________________________________________________________________________ 15etbl6.doc Microsoft Word® Document MS Word® 2002 76KB 2 pages Contents: Appendix B: Evidence Table 6. Studies of Lipid Control _____________________________________________________________________________________________________ 16etbl7.doc Microsoft Word® Document MS Word® 2002 94KB 6 pages Contents: Appendix B: Evidence Table 7. Studies of IFG/IGT Screening and Treatment _____________________________________________________________________________________________________ 17etbl8.doc Microsoft Word® Document MS Word® 2002 43KB 2 pages Contents: Appendix B: Evidence Table 8. Studies of Harms of Screening or Treatment _____________________________________________________________________________________________________ 18etbl9.doc Microsoft Word® Document MS Word® 2002 81KB 6 pages Contents: Appendix B: Evidence Table 9. Studies of Cost, Cost-Effectiveness, or Modeling _____________________________________________________________________________________________________ 19gloss.doc Microsoft Word® Document MS Word® 2002 564KB 2 pages Contents: Appendix B: Evidence Tables Glossary _____________________________________________________________________________________________________ 20fig1.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Figure 1. The "Delta Question" in Screening for Type 2 Diabetes _____________________________________________________________________________________________________ 21fig2.doc Microsoft Word® Document MS Word® 2002 30KB 1 page Contents: Figure 2. Screening for Type 2 Diabetes: Analytic Framework _____________________________________________________________________________________________________ 22tbl1.doc Microsoft Word® Document MS Word® 2002 35KB 1 page Contents: Table 1. Screening for Type 2 Diabetes: Key Questions _____________________________________________________________________________________________________ 23tbl2.doc Microsoft Word® Document MS Word® 2002 47KB 1 page Contents: Table 2. Number Needed to Screen (NNS) for Diabetes to Prevent One Case of Blindness in One Eye by Tight Glycemic Control _____________________________________________________________________________________________________ 24tbl3.doc Microsoft Word® Document MS Word® 2002 47KB 1 page Contents: Table 3. Number Needed to Screen (NNS) for Diabetes to Prevent One Cardiovascular Event by Tight Blood Pressure Control _____________________________________________________________________________________________________
Current as of February 2003
Internet Citation:
Screening for Type 2 Diabetes Mellitus. File Inventory, Systematic Evidence Review Number 19. February 2003. Agency for Healthcare Research and Quality, Rockville, MD. http://www.ahrq.gov/clinic/prev/dbscrinv.htm
Return to Preventive Services Files Download
U.S. Preventive Services Task Force
Clinical Information
AHRQ Home Page
Department of Health and Human Services